Recursion Pharmaceuticals Inc (RXRX)

Currency in USD
2.86
-0.04(-1.21%)
Closed·
2.86+0.01(+0.35%)
·
Trading near 52-week Low
RXRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.772.89
52 wk Range
2.777.18
Key Statistics
Prev. Close
2.89
Open
2.87
Day's Range
2.77-2.89
52 wk Range
2.77-7.18
Volume
15.82M
Average Vol. (3m)
13.81M
1-Year Change
-36.5854%
Book Value / Share
1.94
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RXRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.64
Upside
+132.27%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

3 Buy
5 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.64
(+132.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Hold5.50+92.31%5.00MaintainMay 14, 2026
JPMorgan
Buy10.00+249.65%11.00MaintainApr 30, 2026
BofA Securities
Hold6.00+109.79%7.00MaintainFeb 25, 2026
JPMorgan
Buy11.00+284.62%10.00UpgradeDec 17, 2025
Morgan Stanley
Hold5.00+74.83%4.80MaintainNov 17, 2025

Recursion Pharmaceuticals Inc Earnings Call Summary for Q1/2026

  • Recursion beat Q1 2026 EPS at -$0.22 vs. -$0.26 forecast but missed revenue significantly at $6.47M vs. $16.28M expected (-60.26%)
  • Stock fell 1.84% to $3.20 in pre-market trading following mixed results and substantial revenue shortfall
  • Company reduced cash operating expenses 30% YoY; maintains $665M cash position extending financial runway to early 2028
  • Reaffirmed 2026 operating expense guidance below $390M while advancing clinical pipeline for precision therapies
  • CEO Gibson highlighted operational efficiency and strategic partnerships as key to extending runway without additional financing needs
Last Updated: 05/12/2026, 12:30 PM
Read Full Transcript
Recursion Pharmaceuticals investor slides for Q1/2026
Recursion Q1 2026 slides
Last Update: May 12, 2026
See full investor slides

Earnings

Latest Release
May 06, 2026
EPS / Forecast
-0.22 / -0.26
Revenue / Forecast
6.47M / 16.28M
EPS Revisions
Last 90 days

RXRX Income Statement

Compare RXRX to Peers and Sector

Metrics to compare
RXRX
Peers
Sector
Relationship
P/E Ratio
−2.7x−5.6x−0.5x
PEG Ratio
−0.08−0.090.00
Price / Book
1.5x3.2x2.6x
Price / LTM Sales
22.9x17.0x3.2x
Upside (Analyst Target)
106.9%96.8%55.3%
Fair Value Upside
Unlock−10.1%9.7%Unlock

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
199.54M37.59%576.66M
Other Institutional Investors
183.77M34.62%531.09M
Public Companies & Retail Investors
147.46M27.78%426.15M
Total
530.76M100.00%1.53B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Vanguard Group, Inc.8.89%47,187,759136,373
ARK Investment Management LLC7.58%40,212,769116,215

People Also Watch

353.74
COHR
-2.51%
13.07
POET
-8.00%
890.68
LITE
+0.64%
220.61
NVDA
-0.77%
9.125
ONDS
-5.93%

FAQ

What Is the Recursion Pharmaceuticals (RXRX) Stock Price Today?

The Recursion Pharmaceuticals stock price today is 2.86 USD.

What Stock Exchange Does Recursion Pharmaceuticals Trade On?

Recursion Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Recursion Pharmaceuticals?

The stock symbol for Recursion Pharmaceuticals is "RXRX."

What Is the Recursion Pharmaceuticals Market Cap?

As of today, Recursion Pharmaceuticals market cap is 1.51B USD.

What Is Recursion Pharmaceuticals's Earnings Per Share (TTM)?

The Recursion Pharmaceuticals EPS (TTM) is -1.17.

When Is the Next Recursion Pharmaceuticals Earnings Date?

Recursion Pharmaceuticals will release its next earnings report on Aug 11, 2026.

From a Technical Analysis Perspective, Is RXRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Recursion Pharmaceuticals Stock Split?

Recursion Pharmaceuticals has split 0 times.

How Many Employees Does Recursion Pharmaceuticals Have?

Recursion Pharmaceuticals has 600 employees.

What is the current trading status of Recursion Pharmaceuticals (RXRX)?

As of May 19, 2026, Recursion Pharmaceuticals (RXRX) is trading at a price of 2.86 USD, with a previous close of 2.89 USD. The stock has fluctuated within a day range of 2.77 USD to 2.89 USD, while its 52-week range spans from 2.77 USD to 7.18 USD.

What Is Recursion Pharmaceuticals (RXRX) Price Target According to Analysts?

The average 12-month price target for Recursion Pharmaceuticals is 6.64 USD, with a high estimate of 10 USD and a low estimate of 3 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +132.27% Upside potential.

What Is the RXRX Premarket Price?

RXRX's last pre-market stock price is 2.86 USD. The pre-market share volume is 304,660.00, and the stock has decreased by -0.03, or -1.04%.

What Is the RXRX After Hours Price?

RXRX's last after hours stock price is 2.86 USD, the stock has decreased by 0.01, or 0.35%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.